August 8th 2025
Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.
July 25th 2025
Psychotherapy faces skepticism in psychiatry, yet it remains vital for understanding patients' narratives and enhancing therapeutic relationships.
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Collaborative Role of Providers for Screening, Diagnosis, and Referrals in Postpartum Depression
August 8th 2025Experts discuss that effective management of perinatal mood and anxiety disorders in primary care and obstetrics requires routine screening, clear referral pathways, provider education, and collaborative care to ensure timely diagnosis and treatment.
Efficacy and Safety of Xanomeline/Trospium Chloride and Experience in Treating Schizophrenia
August 4th 2025Panelists discuss how real-world experience with xanomeline/trospium chloride shows efficacy across all 3 symptom domains with manageable gastrointestinal adverse effects that typically resolve within 2 weeks, requiring slow titration and patient education about empty stomach dosing.
Xanomeline/Trospium Chloride for Treatment of Schizophrenia
August 4th 2025Panelists discuss how xanomeline/trospium chloride represents a first-in-class medication with a novel muscarinic mechanism that addresses positive, negative, and cognitive symptoms while avoiding typical antipsychotic adverse effects such as movement disorders and prolactin elevation.
Risk Factors for Postpartum Depression
August 1st 2025Experts discuss that while anyone can experience perinatal mood and anxiety disorders, individuals with personal or family mental health histories, recent trauma, or medication changes are at higher risk, and emphasize the critical importance of informed, individualized medication management during pregnancy and lactation to balance risks, prevent undertreatment, and ensure the well-being of both parent and child.